Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA)

Adam F.M. Stone, Michael A. Mendall, J. Kaski, Tracey M. Edger, P. Risley, J. Poloniecki, A. Camm, T. Northfield
{"title":"Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA)","authors":"Adam F.M. Stone, Michael A. Mendall, J. Kaski, Tracey M. Edger, P. Risley, J. Poloniecki, A. Camm, T. Northfield","doi":"10.1161/01.CIR.0000027820.66786.CF","DOIUrl":null,"url":null,"abstract":"Background—Infection with Helicobacter pylori and Chlamydia pneumoniae is associated with coronary heart disease. We conducted an intervention study using antibiotics against these bacteria in patients with acute coronary syndromes to determine whether antibiotics reduce inflammatory markers and adverse cardiac events. Methods and Results—Patients (n=325) admitted with acute myocardial infarction or unstable angina (acute coronary syndromes) were randomized to receive a 1-week course of 1 of 3 treatment regimens: (1) placebo; (2) amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily); or (3) azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily). Serum fibrinogen, white cell count, and high-sensitivity C-reactive protein were measured at study entry and at 1, 3, and 12 months during follow-up. Cardiac death and readmission with acute coronary syndrome were considered clinical end points. Patients were followed for 1 year. C-reactive protein levels were reduced (P =0.03) in unstable angina patients receiving amoxicillin, and fibrinogen was reduced in both patient groups receiving antibiotics (P =0.06). There were 17 cardiac deaths and 71 readmissions with acute coronary syndrome. No difference in frequency or timing of end points was observed between the 2 antibiotic groups. At 12 weeks, there was a 36% reduction in all end points in patients receiving antibiotics compared with placebo (P =0.02). This reduction persisted during the 1-year follow-up. Neither C pneumoniae nor H pylori antibody status was significantly related to response to treatment. Conclusions—Antibiotic treatment significantly reduced adverse cardiac events in patients with acute coronary syndromes, but the effect was independent of H pylori or C pneumoniae seropositivity.","PeriodicalId":10194,"journal":{"name":"Circulation: Journal of the American Heart Association","volume":"8 1","pages":"1219-1223"},"PeriodicalIF":0.0000,"publicationDate":"2002-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"209","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Journal of the American Heart Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1161/01.CIR.0000027820.66786.CF","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 209

Abstract

Background—Infection with Helicobacter pylori and Chlamydia pneumoniae is associated with coronary heart disease. We conducted an intervention study using antibiotics against these bacteria in patients with acute coronary syndromes to determine whether antibiotics reduce inflammatory markers and adverse cardiac events. Methods and Results—Patients (n=325) admitted with acute myocardial infarction or unstable angina (acute coronary syndromes) were randomized to receive a 1-week course of 1 of 3 treatment regimens: (1) placebo; (2) amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily); or (3) azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily). Serum fibrinogen, white cell count, and high-sensitivity C-reactive protein were measured at study entry and at 1, 3, and 12 months during follow-up. Cardiac death and readmission with acute coronary syndrome were considered clinical end points. Patients were followed for 1 year. C-reactive protein levels were reduced (P =0.03) in unstable angina patients receiving amoxicillin, and fibrinogen was reduced in both patient groups receiving antibiotics (P =0.06). There were 17 cardiac deaths and 71 readmissions with acute coronary syndrome. No difference in frequency or timing of end points was observed between the 2 antibiotic groups. At 12 weeks, there was a 36% reduction in all end points in patients receiving antibiotics compared with placebo (P =0.02). This reduction persisted during the 1-year follow-up. Neither C pneumoniae nor H pylori antibody status was significantly related to response to treatment. Conclusions—Antibiotic treatment significantly reduced adverse cardiac events in patients with acute coronary syndromes, but the effect was independent of H pylori or C pneumoniae seropositivity.
肺炎衣原体和幽门螺杆菌治疗对急性冠状动脉综合征患者炎症和心脏事件标志物的影响:心肌梗死和不稳定心绞痛的抗生素南泰晤士试验(STAMINA)
背景:幽门螺杆菌和肺炎衣原体感染与冠心病有关。我们对急性冠脉综合征患者使用抗生素对抗这些细菌进行了一项干预研究,以确定抗生素是否能减少炎症标志物和不良心脏事件。方法和结果:入院的急性心肌梗死或不稳定型心绞痛(急性冠状动脉综合征)患者(n=325)随机接受3种治疗方案中的1种,疗程为1周:(1)安慰剂;(2)阿莫西林(500毫克,每日2次)、甲硝唑(400毫克,每日2次)、奥美拉唑(20毫克,每日2次);或(3)阿奇霉素(500毫克,每日一次),甲硝唑(400毫克,每日两次),奥美拉唑(20毫克,每日两次)。血清纤维蛋白原、白细胞计数和高敏c反应蛋白在研究开始时和随访1、3、12个月时测定。心源性死亡和急性冠状动脉综合征再入院被认为是临床终点。随访1年。服用阿莫西林的不稳定型心绞痛患者c反应蛋白水平降低(P =0.03),服用抗生素的两组患者纤维蛋白原水平均降低(P =0.06)。17例心脏死亡,71例急性冠状动脉综合征再入院。在两个抗生素组之间观察到终点的频率或时间没有差异。在12周时,与安慰剂相比,接受抗生素治疗的患者的所有终点都减少了36% (P =0.02)。这种减少在1年的随访中持续存在。肺炎C和幽门螺杆菌抗体状态与治疗反应均无显著相关性。结论:抗生素治疗可显著减少急性冠脉综合征患者的不良心脏事件,但其效果与幽门螺杆菌或肺炎C菌血清阳性无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信